

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 13 returned.**☐ 1. Document ID: US 6296853 B1

L1: Entry 1 of 13

File: USPT

Oct 2, 2001

US-PAT-NO: 6296853

DOCUMENT-IDENTIFIER: US 6296853 B1

TITLE: E6 binding proteins

DATE-ISSUED: October 2, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Androphy; Elliot J.	Natick	MA		
Chen; Jason J.	Boston	MA		

US-CL-CURRENT: 424/204.1; 435/5, 435/7.23, 435/7.6, 514/12, 530/300, 530/350, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 2. Document ID: US 5989804 A

L1: Entry 2 of 13

File: USPT

Nov 23, 1999

US-PAT-NO: 5989804

DOCUMENT-IDENTIFIER: US 5989804 A

TITLE: E6 binding proteins

DATE-ISSUED: November 23, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Androphy; Elliot J.	Natick	MA		
Chen; Jason J.	Boston	MA		

US-CL-CURRENT: 435/5; 435/7.23, 435/7.6, 435/7.7, 435/7.71, 435/7.72, 435/7.92, 514/12, 530/300, 530/350, 536/23.5, 536/23.72, 930/220

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 5821051 A

L1: Entry 3 of 13

File: USPT

Oct 13, 1998

US-PAT-NO: 5821051

DOCUMENT-IDENTIFIER: US 5821051 A

TITLE: E6 binding proteins

DATE-ISSUED: October 13, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Androphy</u> ; Elliot	Natick	MA		
Chen; Jason J.	Boston	MA		

US-CL-CURRENT: 435/5; 530/350, 530/352, 530/357, 530/358

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 4. Document ID: US 5792833 A

L1: Entry 4 of 13

File: USPT

Aug 11, 1998

US-PAT-NO: 5792833

DOCUMENT-IDENTIFIER: US 5792833 A

TITLE: E2 binding proteins

DATE-ISSUED: August 11, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Androphy</u> ; Elliot J.	Natick	MA		
Breiding; David E.	Somerville	MA		

US-CL-CURRENT: 530/350; 530/300

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 5. Document ID: US 5770384 A

L1: Entry 5 of 13

File: USPT

Jun 23, 1998

US-PAT-NO: 5770384

DOCUMENT-IDENTIFIER: US 5770384 A

TITLE: Method for determining compound interaction with E2 binding proteins

DATE-ISSUED: June 23, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Androphy</u> ; Elliot J.	Natick	MA		
Breiding; David E.	Somerville	MA		

US-CL-CURRENT: 435/7.8; 435/5, 435/69.1, 435/69.7, 435/7.1, 435/7.93, 514/2, 530/300,  
530/350, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 6. Document ID: US 5674835 A

L1: Entry 6 of 13

File: USPT

Oct 7, 1997

US-PAT-NO: 5674835

DOCUMENT-IDENTIFIER: US 5674835 A

TITLE: Papillomaviral expression inhibitors

DATE-ISSUED: October 7, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Androphy; Elliot J.	Natick	MA		
Lowy; Douglas R.	Washington	DC		
Schiller; John T.	Silver Springs	MD		

US-CL-CURRENT: 514/2; 435/235.1, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 7. Document ID: US 5667965 A

L1: Entry 7 of 13

File: USPT

Sep 16, 1997

US-PAT-NO: 5667965

DOCUMENT-IDENTIFIER: US 5667965 A

TITLE: Papillomavirus E2 trans-activation repressors

DATE-ISSUED: September 16, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Androphy; Elliot J.	Natick	MA		
Barsoum; James G.	Lexington	MA		

US-CL-CURRENT: 435/5; 435/235.1, 435/320.1, 435/69.1, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 8. Document ID: US 5656599 A

L1: Entry 8 of 13

File: USPT

Aug 12, 1997

US-PAT-NO: 5656599

DOCUMENT-IDENTIFIER: US 5656599 A

TITLE: Papillomavirus E2 trans-activation repressors

DATE-ISSUED: August 12, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Androphy</u> ; Elliot J.	Natick	MA		
Barsoum; James G.	Lexington	MA		

US-CL-CURRENT: 514/12; 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KWIC

☐ 9. Document ID: US 5616559 A

L1: Entry 9 of 13

File: USPT

Apr 1, 1997

US-PAT-NO: 5616559

DOCUMENT-IDENTIFIER: US 5616559 A

TITLE: Papillomavirus E2 trans-activation repressors

DATE-ISSUED: April 1, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Androphy</u> ; Elliot J.	Natick	MA		
Barsoum; James G.	Lexington	MA		

US-CL-CURRENT: 514/12; 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KWIC

☐ 10. Document ID: US 5595884 A

L1: Entry 10 of 13

File: USPT

Jan 21, 1997

US-PAT-NO: 5595884

DOCUMENT-IDENTIFIER: US 5595884 A

TITLE: Papillomavirus E2 transactivation repressor proteins and DNA

DATE-ISSUED: January 21, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Androphy</u> ; Elliot J.	Natick	MA		
Barsoum; James G.	Lexington	MA		

US-CL-CURRENT: 435/69.1; 435/252.31, 435/252.33, 435/252.34, 435/252.35, 435/254.21,  
435/320.1, 435/348, 435/354, 435/358, 435/363, 435/364, 435/365, 435/366, 514/2,  
530/350, 530/826, 536/23.72, 930/220

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

[Generate Collection](#)[Print](#)

Terms	Documents
Androphy.in.	13

**Display Format:** [CIT](#) [Change Format](#)[Previous Page](#)[Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**☐ 1. Document ID: US 6492116 B1

L6: Entry 1 of 2

File: USPT

Dec 10, 2002

US-PAT-NO: 6492116

DOCUMENT-IDENTIFIER: US 6492116 B1

TITLE: Assay for identifying inhibitors of the interaction between proteins p53 and dm2

DATE-ISSUED: December 10, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chene; Patrick	Mulhouse			FR
Hochkeppel; Heinz-Kurt	Aesch			CH

US-CL-CURRENT: [435/6](#); [435/91.2](#), [436/501](#), [536/23.1](#), [536/24.3](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[KWC](#)☐ 2. Document ID: US 5578444 A

L6: Entry 2 of 2

File: USPT

Nov 26, 1996

US-PAT-NO: 5578444

DOCUMENT-IDENTIFIER: US 5578444 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: November 26, 1996

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: [435/6](#); [435/7.23](#), [536/23.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[KWC](#)

[Generate Collection](#)[Print](#)

Terms	Documents
papillomavirus and E6 and inhibiting binding.clm.	2

**Display Format:**[CIT](#)[Change Format](#)[Previous Page](#)[Next Page](#)

**WEST**

Generate Collection

Print

L7: Entry 5 of 7

File: DWPI

Jan 15, 1998

DERWENT-ACC-NO: 1998-100996  
DERWENT-WEEK: 200208  
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Compounds binding to MDM2 protein and inhibit its interaction with p53 - useful in, e.g. diagnosis and treatment of cancer and viral infections and identifying binding agents

INVENTOR: BOTTGER, A; BOTTGER, V ; CHENE, P ; FURET, P ; GARCIA-ECHEVERRIA, C ; HOCHKEPPEL, H ; LANE, D ; PICKSLEY, S ; CHNE, P ; BOETTGER, A ; BOETTGER, V ; PICKSLEY, S M

PRIORITY-DATA: 1997GB-0007041 (April 7, 1997), 1996GB-0014197 (July 5, 1996), 2001AU-0014979 (January 15, 2001)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9801467 A2	January 15, 1998	E	045	C07K014/00
AU 200114979 A	December 6, 2001		000	C07K014/00
AU 9738479 A	February 2, 1998		000	C07K014/00
EP 958305 A2	November 24, 1999	E	000	C07K014/00
NZ 333609 A	August 25, 2000		000	C07K007/06
JP 2001500365 W	January 16, 2001		113	C12N015/09
US 20010018511 A1	August 30, 2001		000	A61K038/00

INT-CL (IPC): A61 K 38/00; A61 K 38/08; A61 K 38/10; A61 K 38/16; A61 K 45/00; A61 K 48/00; A61 P 35/00; C07 K 5/00; C07 K 7/06; C07 K 7/08; C07 K 14/00; C07 K 14/82; C12 N 15/09; C12 Q 1/68; G01 N 33/53

ABSTRACTED-PUB-NO: US20010018511A  
BASIC-ABSTRACT:

Compound (C1), or its derivative capable of binding to an oncogenic protein MDM2 (especially human DM2) and specifically inhibiting or block the binding of MDM2 to the p53 (especially human) protein, in vitro or in vivo, is new. Also claimed are: (1) induction of growth arrest or apoptosis in tumour cells comprising a wild-type p53 and non-elevated levels of MDM2 by inhibiting interaction between these compounds, in vivo or in vitro; (2) treatment of hyperproliferative disease by inhibiting the interaction in (1), and (3) preparation of a peptide or a derivative by: (a) reacting a fragment of the peptide having a free COOH group or its reactive derivative with a complementary fragment having an amino group with at least 1 free H atom or its reactive fragment resulting in the formation of a peptide bond, and (b) removing a present protecting group or derivatising the peptide or a derivative.

USE - C1 may be used to identify molecules that bind to MDM2 and to identify/design inhibitors of MDM2/p53 binding. C1 may also be used to purify binding partners especially MDM2, diagnose disease by, e.g. measuring levels of MDM2 in blood of cancer and leukaemia patients and for treatment or prevention of disease involving p53/MDM2 interactions, especially tumours and viral infections. C1 can be administered nasally, rectally, orally or by injection.

ADVANTAGE - By interfering with MDM2/p53 interaction, C1 can activate p53 function and accumulation in normal cells. C1 which mimics the MDM2 binding site in p53, have a



significantly greater blocking activity compared with wild-type p53.

ABSTRACTED-PUB-NO:

WO 9801467A

EQUIVALENT-ABSTRACTS:

Compound (C1), or its derivative capable of binding to an oncogenic protein MDM2 (especially human DM2) and specifically inhibiting or block the binding of MDM2 to the p53 (especially human) protein, in vitro or in vivo, is new. Also claimed are: (1) induction of growth arrest or apoptosis in tumour cells comprising a wild-type p53 and non-elevated levels of MDM2 by inhibiting interaction between these compounds, in vivo or in vitro; (2) treatment of hyperproliferative disease by inhibiting the interaction in (1), and (3) preparation of a peptide or a derivative by: (a) reacting a fragment of the peptide having a free COOH group or its reactive derivative with a complementary fragment having an amino group with at least 1 free H atom or its reactive fragment resulting in the formation of a peptide bond, and (b) removing a present protecting group or derivatising the peptide or a derivative.

USE - C1 may be used to identify molecules that bind to MDM2 and to identify/design inhibitors of MDM2/p53 binding. C1 may also be used to purify binding partners especially MDM2, diagnose disease by, e.g. measuring levels of MDM2 in blood of cancer and leukaemia patients and for treatment or prevention of disease involving p53/MDM2 interactions, especially tumours and viral infections. C1 can be administered nasally, rectally, orally or by injection.

ADVANTAGE - By interfering with MDM2/p53 interaction, C1 can activate p53 function and accumulation in normal cells. C1 which mimics the MDM2 binding site in p53, have a significantly greater blocking activity compared with wild-type p53.

ABSTRACTED-PUB-NO: US20010018511A

EQUIVALENT-ABSTRACTS: Compound (C1), or its derivative capable of binding to an oncogenic protein MDM2 (especially human DM2) and specifically inhibiting or block the binding of MDM2 to the p53 (especially human) protein, in vitro or in vivo, is new. Also claimed are: (1) induction of growth arrest or apoptosis in tumour cells comprising a wild-type p53 and non-elevated levels of MDM2 by inhibiting interaction between these compounds, in vivo or in vitro; (2) treatment of hyperproliferative disease by inhibiting the interaction in (1), and (3) preparation of a peptide or a derivative by: (a) reacting a fragment of the peptide having a free COOH group or its reactive derivative with a complementary fragment having an amino group with at least 1 free H atom or its reactive fragment resulting in the formation of a peptide bond, and (b) removing a present protecting group or derivatising the peptide or a derivative.

USE - C1 may be used to identify molecules that bind to MDM2 and to identify/design inhibitors of MDM2/p53 binding. C1 may also be used to purify binding partners especially MDM2, diagnose disease by, e.g. measuring levels of MDM2 in blood of cancer and leukaemia patients and for treatment or prevention of disease involving p53/MDM2 interactions, especially tumours and viral infections. C1 can be administered nasally, rectally, orally or by injection. ADVANTAGE - By interfering with MDM2/p53 interaction, C1 can activate p53 function and accumulation in normal cells. C1 which mimics the MDM2 binding site in p53, have a significantly greater blocking activity compared with wild-type p53. WO 9801467A

CHOSEN-DRAWING: Dwg.0/0

**WEST**

Generate Collection

Print

L7: Entry 6 of 7

File: DWPI

Mar 27, 1997

DERWENT-ACC-NO: 1997-203038

DERWENT-WEEK: 199911

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Assay for inhibitors of p53 to dm2 binding - comprising p53, dm2 and DNA sequence specifically binding p53 specific DNA binding domain

INVENTOR: CHENE, P; HOCHKEPPEL, H

PRIORITY-DATA: 1995EP-0810576 (September 18, 1995)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9711367 A1	March 27, 1997	E	030	G01N033/50
ZA 9607826 A	May 28, 1997		029	G01N000/00
AU 9671272 A	April 9, 1997		000	G01N033/50
EP 859956 A1	August 26, 1998	E	000	G01N033/50

INT-CL (IPC): C12 Q 1/68; G01 N 0/00; G01 N 33/50; G01 N 33/53; G01 N 33/68

ABSTRACTED-PUB-NO: WO 9711367A

## BASIC-ABSTRACT:

Testing the effect of a substance on the binding of a dm2 protein to p53, comprises the investigation of complex formation in a mixture, comprising: (a) p53 having specific DNA binding, oligomerisation and dm2 binding properties; (b) dm2 having the p53 binding domain; (c) DNA sequence specifically binding the p53 specific DNA binding domain; and (d) substance to be tested.

USE - The method (kit provided) can be used to identify agents which inhibit the binding of dm2 to p53, thereby releasing p53 and promoting its tumour suppression activity in tumour cells.

ADVANTAGE - The method can identify agents which inhibit the interaction between p53 and dm2, while allowing p53 specific DNA binding and preventing p53 conformation disruption.

ABSTRACTED-PUB-NO: WO 9711367A

## EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

## WEST Search History

DATE: Sunday, January 12, 2003

**Set Name Query**  
**side by side**

**Hit Count Set Name**  
**result set**

*DB=DWPI; PLUR=YES; OP=ADJ*

L7 Chene P.in.

7 L7

*DB=USPT; PLUR=YES; OP=ADJ*

L6 papillomavirus and E6 and inhibiting binding.clm.

2 L6

L5 papillomavirus and E6 and binding.clm.

86 L5

L4 papillomavirus and E6 and binding

292 L4

L3 papillomavirus

1640 L3

L2 binding papilomavirus

0 L2

L1 Androphy.in.

13 L1

END OF SEARCH HISTORY